Skip to main content
GOSS
NASDAQ Life Sciences

Gossamer Bio Reports Worsening Q1 Loss, Reiterates Going Concern Amidst Nasdaq Delisting Threat & Lawsuit

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.333
Mkt Cap
$79.797M
52W Low
$0.314
52W High
$3.87
52W Position info
6.0% above low
Off High info
91% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

GOSS is trading near its 52-week low of $0.314 (6.0% above the low) on light trading volume (0.3× avg).

Summary

Gossamer Bio's Q1 report highlights severe financial distress with increased losses, dwindling cash, a reiterated going concern warning, a Nasdaq delisting notice, and a new class-action lawsuit, alongside a significant stock option repricing.


Key Events · Earnings and Guidance · GOSS

  • Worsening Financial Performance

    Net loss for Q1 2026 increased to $46.7 million, up from $36.6 million in Q1 2025. Cash, cash equivalents, and marketable securities decreased to $99.2 million as of March 31, 2026, from $136.9 million at December 31, 2025.

  • Reiterated Going Concern Warning

    The company explicitly states that existing cash and cash equivalents are insufficient to fund operations for at least one year, projecting a cash runway only into the first quarter of 2027.

  • Nasdaq Delisting Notice

    Gossamer Bio received a notice from Nasdaq on April 9, 2026, for failing to meet the minimum $1.00 bid price requirement, initiating delisting procedures.

  • Class Action Lawsuit Filed

    A putative class action lawsuit was filed on March 31, 2026, alleging false and misleading statements and failure to disclose material adverse facts between June 2025 and February 2026.


Analysis · GOSS · Life Sciences

Gossamer Bio's first-quarter report reveals a deepening financial crisis, with net losses increasing to $46.7 million and cash, cash equivalents, and marketable securities declining to $99.2 million, down from $136.9 million at year-end 2025. The company explicitly reiterates its 'going concern' warning, projecting a cash runway only into Q1 2027. This dire financial situation is compounded by a Nasdaq delisting notice received in April 2026 for failing to meet the minimum bid price, and a class-action lawsuit filed in March 2026 alleging securities fraud. The company also detailed a significant stock option repricing in March 2026 for 48.7 million options to $0.45 per share, a clear sign of distress and an attempt to retain employees amidst the challenges.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 51.2% of the 201 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GOSS was trading at $0.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.8M. The 52-week trading range was $0.31 to $3.87. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GOSS - Latest Insights

GOSS
Sep 23, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.19
Real-time Price: $9.88 info
Change: -$1.31 (-12%) info
Market Cap: $59.7M info
GOSS
Sep 23, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $11.00
Real-time Price: $9.88 info
Change: -$1.12 (-10%) info
Market Cap: $59.7M info
GOSS
Sep 16, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $10.93
Real-time Price: $9.88 info
Change: -$1.05 (-10%) info
Market Cap: $59.7M info
GOSS
Sep 11, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.1562
Real-time Price: $9.88 info
Change: Reverse Stock Split info
Market Cap: $59.7M info
GOSS
Sep 11, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.1562
Real-time Price: $9.88 info
Change: Reverse Stock Split info
Market Cap: $59.7M info